A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36) Article

Web of Science: 000769937700074
Industry Collaboration International Collaboration

Cited authors

  • Seiwert TY, Haddad RI, Johnson D, Gillison M, Keilholz U, Tahara M, Machiels JP, Deeken J, Villaflor V, Su Y, Guthrie T, Shin DM, De Block K, Meirovitz A, Chien D, Tagliaferri M, Zalvesky J, Harrington K

Publication date

  • 2022

International Standard Serial Number (ISSN)

  • 0360-3016

Number of pages

  • 2

Start page

  • E36

End page

  • E37


  • 112


  • 5